Want to see JP:4883 full AI Analyst Report?
4883 Stock Chart & Stats
¥56.00
-¥3.00(-2.91%)
At close: 4:00 PM EST
¥56.00
-¥3.00(-2.91%)
Day’s Range― - ―
52-Week Range¥29.00 - ¥97.00
Previous CloseN/A
Volume5.80M
Average Volume (3M)719.68K
Market Cap
¥3.44B
Enterprise Value¥369.62
Total Cash (Recent Filing)¥2.81B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.80
Shares Outstanding104,374,100
10 Day Avg. Volume617,120
30 Day Avg. Volume719,680
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)1.55
Price to Sales (P/S)0.00
P/FCF Ratio-2.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22.2
Revenue Forecast (FY)¥800.00M
Bulls Say, Bears Say
Bulls Say
Proprietary Epigenome-modulation PlatformA proprietary epigenome-modulation platform is a durable competitive asset: it can generate multiple discovery-stage programs, enable platform-driven efficiencies in R&D, and build IP that supports sustained differentiation versus competitors across 2–6+ months and into later stages.
Pipeline Targeting Rare/intractable DiseasesA focus on rare and intractable diseases provides structural advantages: clearer regulatory pathways, potential orphan incentives, and concentrated patient populations that can enable faster proof-of-concept and higher pricing power if clinical success is achieved, supporting durable commercial potential.
Low Reported Debt / Conservative LeverageVery low reported debt reduces default and interest-service risk, preserving strategic optionality. For a pre-revenue biotech this conservatism supports the ability to pursue partnerships or equity raises without immediate debt constraints, sustaining runway flexibility over the medium term.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow, and worsening burn in 2025, create ongoing funding needs. This elevates dilution and refinancing risk, can interrupt R&D timelines if capital access tightens, and pressures long-term program continuity absent new funding sources.
Minimal-to-zero Revenue; Recurring Large LossesThe absence of meaningful revenue and persistent multi-year net losses mean there is no operating margin cushion. The company remains dependent on external financing to sustain development, limiting self-funded growth and increasing execution risk for converting pipeline assets into commercial cash flow.
Shrinking Equity BaseA materially declining equity base reflects cumulative losses and reduces balance-sheet resilience. That smaller capital buffer constrains financing alternatives, raises the probability of dilutive raises or strategic partnerships, and weakens ability to absorb setbacks in clinical development.
Modalis Therapeutics Corporation News
4883 FAQ
What was Modalis Therapeutics Corporation’s price range in the past 12 months?
Modalis Therapeutics Corporation lowest stock price was ¥29.00 and its highest was ¥97.00 in the past 12 months.
What is Modalis Therapeutics Corporation’s market cap?
Modalis Therapeutics Corporation’s market cap is ¥3.44B.
When is Modalis Therapeutics Corporation’s upcoming earnings report date?
Modalis Therapeutics Corporation’s upcoming earnings report date is Nov 11, 2026 which is in 86 days.
How were Modalis Therapeutics Corporation’s earnings last quarter?
Modalis Therapeutics Corporation released its earnings results on Aug 10, 2026. The company reported -¥6.32 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Modalis Therapeutics Corporation overvalued?
According to Wall Street analysts Modalis Therapeutics Corporation’s price is currently Overvalued.
Does Modalis Therapeutics Corporation pay dividends?
Modalis Therapeutics Corporation does not currently pay dividends.
What is Modalis Therapeutics Corporation’s EPS estimate?
Modalis Therapeutics Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Modalis Therapeutics Corporation have?
Modalis Therapeutics Corporation has 104,374,100 shares outstanding.
What happened to Modalis Therapeutics Corporation’s price movement after its last earnings report?
Modalis Therapeutics Corporation reported an EPS of -¥6.32 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.125%.
Which hedge fund is a major shareholder of Modalis Therapeutics Corporation?
Currently, no hedge funds are holding shares in JP:4883
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Modalis Therapeutics Corporation
Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.
Technical Analysis
Solasia Pharma KK
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Symbio Pharmaceuticals Limited
―
Cyfuse Biomedical K.K.
―